IRIS
BOLZONI, Marina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.128
EU - Europa 1.929
AS - Asia 1.269
AF - Africa 42
Continente sconosciuto - Info sul continente non disponibili 8
SA - Sud America 1
Totale 5.377
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.096
CN - Cina 899
SE - Svezia 486
IE - Irlanda 432
FI - Finlandia 394
IT - Italia 238
TR - Turchia 192
DE - Germania 169
SG - Singapore 136
UA - Ucraina 56
CI - Costa d'Avorio 39
CA - Canada 32
BE - Belgio 28
AT - Austria 27
RO - Romania 27
IN - India 26
CZ - Repubblica Ceca 18
GB - Regno Unito 16
FR - Francia 13
EU - Europa 8
NL - Olanda 7
ES - Italia 6
HK - Hong Kong 5
CM - Camerun 3
AE - Emirati Arabi Uniti 2
BG - Bulgaria 2
CH - Svizzera 2
HR - Croazia 2
IR - Iran 2
SM - San Marino 2
TW - Taiwan 2
CO - Colombia 1
DK - Danimarca 1
IL - Israele 1
KH - Cambogia 1
KZ - Kazakistan 1
LU - Lussemburgo 1
MD - Moldavia 1
PH - Filippine 1
PK - Pakistan 1
RS - Serbia 1
Totale 5.377
Salva come PNG Salva come JPEG
Città #
Dublin 431
Chandler 421
Beijing 207
Izmir 165
Dearborn 157
Ashburn 140
Nanjing 137
Parma 137
Jacksonville 133
Ann Arbor 106
Boardman 98
Singapore 96
Princeton 86
Shanghai 86
New York 63
San Mateo 59
Shenyang 59
Kunming 57
Nanchang 42
Düsseldorf 41
Hebei 41
Abidjan 39
Wilmington 37
Toronto 31
Jinan 30
Brussels 28
Helsinki 28
Jiaxing 28
Tianjin 28
Kocaeli 27
Vienna 27
Changsha 23
Hefei 23
Focsani 22
Des Moines 19
Los Angeles 18
Bremen 17
Brno 16
Milan 15
Seattle 15
Norwalk 13
Santa Clara 13
Hangzhou 11
Munich 10
Pune 10
Redmond 10
Zhengzhou 10
Chengdu 9
Guangzhou 9
Piacenza 9
Mestre 8
Fuzhou 7
Palermo 7
Taizhou 7
Woodbridge 7
Chongqing 6
Wuhan 6
Dallas 5
Houston 5
Madrid 5
Ningbo 5
Philadelphia 5
Torino 5
Borås 4
Cambridge 4
Central 4
Fremont 4
Rockville 4
Rome 4
Timisoara 4
Ahmedabad 3
Chicago 3
Edinburgh 3
Jinhua 3
Leawood 3
Nürnberg 3
Simi Valley 3
Xian 3
Baotou 2
Camparada 2
Catania 2
Deiva Marina 2
Dubai 2
Grafing 2
Haikou 2
Huizen 2
London 2
Mountain View 2
Mumbai 2
Old Bridge 2
Orange 2
Raritan 2
Redwood City 2
Reggio Emilia 2
Scottsdale 2
Sofia 2
Southend 2
Taipei 2
Taiyuan 2
Vignola 2
Totale 3.511
Salva come PNG Salva come JPEG
Nome #
Hypoxia and Hypoxia Inducible Factor (HIF)-1{alpha} in Multiple Myeloma: Effect on the Pro-Angiogenic Signature of Myeloma Cells and the Bone Marrow Microenvironment 103
Are the Myeloma bone microevironment cells tumoral or not? 102
Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20 100
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 99
Ammonium Production and Glutamine-Addiction of Myeloma Cells: New Attractive Targets in Multiple Myeloma 98
Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells 96
CC-4047 (Pomalidomide) inhibits multiple myeloma-induced osteoclast formation targeting RANKL in the bone marrow microenvironment 93
HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients 93
Hypoxia and hypoxia inducible factor (HIF)-1α in Multiple Myeloma patients: role in the angiogenic switch 92
Bone marrow CX3CL1/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients 92
Activation of non-canonical wnt pathway in human mesenchymal cells affects osteogenic differentiation: a potential target in Multiple Myeloma microenvironment 91
Glutamine dependence and PIK3CA mutations in colon-rectal cancer cells: ATF4 enters the stage 89
The homeobox gene HOXB7 regulates the production of pro-angiogenic molecole by myeloma cells and it is a target in myeloma-induced angiogenesis 88
The Immunomodulatory drugs Lenalidomide and Pomalidomide inhibit multiple myeloma-induced osteoclast formation and RANKL/OPG ratio in myeloma microenvironment targeting the expression of adhesion molecules 87
HOXB7 is a key gene involved in Myeloma cell growth and Myeloma-induced angiogenesis in Multiple Myeloma patients 86
The IMID CC-4047 (Pomalidomide) inhibits myeloma-induced osteoclast formation 85
Modulation of non canonical wnt5a/ror2 signaling pathway in human mesenchymal cells increases osteogenic differentiation counterbalancing the effect of myeloma cells 81
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation 81
Possible targets to treat myeloma-related osteoclastogenesis 80
Hypoxia-Inducible Factor (HIF)-1 alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo 78
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 78
Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation 77
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells 77
Oxygen tension in the bone marrow (BM) of patients with malignant and indolent monoclonal gammopathy: role of hypoxia and hypoxia-inducible factor (HIF)-1{alpha} in the regulation of gene expression and pro-angiogenic profiles of CD138+ cells 75
HOXB7 is critically involved in Multiple Myeloma-induced angiogenic switch 75
The activation of wnt5a-mediated non canonical wnt signaling in human bone marrow osteoprogenitor cells increases osteoblastogenesis and counterbalances the inhibitory effect of myeloma cells on ror2/fzd5 expression 75
Generation and Characterization of Microvesicles after Daratumumab Interaction with Myeloma Cells 73
Non canonical wnt signal pathway (Wnt5a/ror2) activation stimulates the osteogenic differentiation process of bone mesenchymal cells being a potential target in multiple myeloma bone disease 72
The anti-myeloma effect of Lenalidomide is increased by hypoxia-inducible factor (HIF)-1a inhibition in multiple myeloma cells both in vitro and in vivo 72
Bone marrow monocyte / macrophage derived activin a mediates the osteoclastogenic effects of IL-3 in myeloma 71
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 71
Use of traffic crash as a risk assessment scale in hospitalized seniors: A perspective observational study 70
Galectin-1 Is Highly Expressed By Myeloma Cells and the Bone Marrow Microenvironment and Its Suppression Delineates a New Therapeutic in Vitro and in Vivo Strategy in Multiple Myeloma 69
Myeloma cells inhibit the non-canonical wnt co-receptor ror2 in human mesenchymal/osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on mm-induced impairment of the osteogenic differentiation process 67
Increased osteocyte apoptosis in Multiple Myeloma patients: a potential role in bone remodeling alterations related to osteolytic bone lesions 67
Trascriptome Analysis of Bone Marrow CD14+ Monocytes Revealed Differential Expression Profiles in Symptomatic Multiple Myeloma (MM) Compared to Smoldering MM and Monoclonal Gammopathy of Undetermined Significance 67
EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA 67
Hypoxia-inducible factor (HIF)-1 is a therapeutic target in myeloma-induced angiogenesis and bone destruction in vitro and in vivo 66
In vitro and In vivo evidences of osteocytes involvement in myeloma-induced osteolysis 65
Bortezomib improves bone integrity in multiple myeloma patients by blocking osteocyte death and autophagy 65
Bone marrow CD14+ cells show different transcriptional profiles in Multiple Myeloma (MM) as compared to smoldering MM and MGUS: overexpression of IL21R and its involvement in osteoclastogenesis 65
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts 65
Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients 64
Angiogenesis and multiple myeloma 64
Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations 63
Hypoxia-Inducible Factor (HIF)-1a Is A Therapeutic Target in Myeloma-Induced Angiogenesis and Bone Destruction in Vivo 63
Oncolytic Virotherapy in Multiple Myeloma: A Possible Alternative Role of Bovine Viruses 63
The link between bone microenvironment and immune cells in multiple myeloma: Emerging role of CD38 63
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo 62
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties 62
Il mieloma multiplo nell'era dei nuovi farmaci. Patogenesi 61
Proteasome Inhibitors Block Myeloma-Induced Osteocyte Death in Vitro and in Vivo in Multiple Myeloma Patients 61
Relationship between bone imaging features and bone marrow cytokine and chemokine profiles in patients with monoclonal gammopathy 60
Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche 59
Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity 58
Lenalidomide Increases Human Dendritic Cell Maturation in Multiple Myeloma Modulating Both Monocyte Differentiation and Mesenchymal Stromal Cell Inhibitory Properties through Ikaros and Casein Kinase 1 Degradation, Respectively 58
Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma 57
Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin? 57
The osteoblastic niche in the context of multiple myeloma 55
The Myeloma Cells Escape from Bone Marrow to Skin Extramedullary Localization upon Bortezomib Resistance: Role of CXCR4 53
Relationship between presence of osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: role of chemokine (C-C motif) ligand 20 52
Relationship between skeletal involvement, cytogenetic features and bone marrow profiles of cytokines and chemokines in patients with monoclonal gammopathy 51
Interleukin-3 induces activin A in bone marrow monocytes: role in multiple myeloma patients 50
Bisphosphonates in multiple myeloma: Preclinical and clinical data. 50
Overexpression of Pro-Osteoclastogenic Cytokine Receptors and Chemokines By Bone Marrow CD14(+) Monocytes of Multiple Myeloma (MM) Patients As Compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): Role of Interleukin(IL)-21 Receptor/IL-21 Axis in MM-Induced Osteoclastogenesis 50
Transcriptional and proteomic profiles of bone marrow CD14+ cells in multiple myeloma (MM) compared to smoldering MM and MGUS: overexpression of Interleukin (IL)-21 receptor and its involvement in MM-induced osteoclastogenesis 49
IL3 Induces Osteoclastogenesis In Vivo and Is Modulated By Bone Marrow Monocyte / Macrophage Derived Activin A 48
Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction 48
Proteasome inhibitors modulate osteocyte death and autophagy in multiple myeloma 48
The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors 47
Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells 46
The potential of inhibiting glutamine uptake as a therapeutic target for multiple myeloma 46
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules 46
Hypoxia-Inducible Factor (HIF)-1α Is a Therapeutic Target in Myeloma-Induced Angiogenesis 46
Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with Multiple Myeloma bone disease 45
The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide 43
High ASCT2 activity as a marker of extracellular glutamine dependence in ammoniagenic multiple myeloma cell lines 41
New insights into osteogenic and chondrogenic differentiation of human bone marrow mesenchymal stem cells and their potential clinical applications for bone regeneration in pediatric orthopaedics 38
Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD+ 38
NAD⁺-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model 38
Myeloma-Induced osteocyte death was blunted by proteasome inhibitors through the modulation of autophagy 37
Ectoenzymes and Their Products As Communicators in the Human Myeloma Niche 36
Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: Impact on myeloma-induced alterations of bone remodeling 34
Role of osteocytes in myeloma bone disease: Anti-sclerostin antibody as new therapeutic strategy 27
Myeloma and osteoclast relationship 22
Randomised controlled prospective study of the use of adhesive elastic tape for the control of hand oedema in patients with a wrist fracture treated in a cast: a study protocol 18
Assessing satisfaction in simulation among nursing students: psychometric properties of the Satisfaction with Simulation Experience - Italian Version scale 14
Totale 5.554
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.165
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.165
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020594 0 0 36 14 46 128 105 17 61 105 36 46
2020/2021358 17 29 13 5 63 9 12 4 112 37 36 21
2021/2022402 7 1 8 42 12 8 36 37 29 40 32 150
2022/20231.694 199 193 124 109 131 183 47 107 519 31 41 10
2023/2024598 24 53 13 15 40 185 50 25 13 37 38 105
2024/2025231 46 96 89 0 0 0 0 0 0 0 0 0
Totale 5.554